Gastrointestinal Stromal Tumor clinical trials at UCSF

1 research study open to eligible people

A gastrointestinal stromal tumor is a type of cancer that starts in the digestive system. UCSF is running a trial to see if a new drug combination, CGT9486 and Sunitinib, works better than Sunitinib alone. This trial is in Phase 3 and involves multiple international centers.

Showing trials for

  • (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

    open to eligible people ages 18 years and up

    This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being randomized in a 1:1 manner.

    San Francisco, California and other locations

Last updated: